Ocular Therapeutix (OCUL) logo

Ocular Therapeutix (OCUL) stock

After-hours Fri
$5.60
+0.54%

Eye medicines, worth $1.3BSmall-cap biotech

Close $5.57 -4.95%

Why is OCUL down?

Down 48% in 3 months while the S&P 500 fell 10%.

  • It filed a prospectus for an offering of shares on Sep 30, 2025.

Sources: Price history, Nov 20, 2026; Prospectus supplement, Sep 30, 2025; Annual reports, Dec 31, 2025

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time OCUL moves

Free account, no card. An optional alert when OCUL moves or its score changes.Pro, $1 for a first month. An optional alert when OCUL moves or its score changes.Pro, 7 days free with a card. An optional alert when OCUL moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on OCUL →4 more reasons why OCUL is down, from its filings, with the timeline and its peers, for Pro members.
Quality Score
-8
Poor
In its industry
#241of 273
Checks firing
0of 14
Trending down
From 52-week high
-66.1%
under its best in a year

OCUL's Quality Score was unchanged on Fri, Nov 20, at -8.

Follow OCUL's trial news. Pro members can get an alert when Ocular Therapeutix files news, and see its trials, share raises, and its CEO's filings.

Get an alert when OCUL files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis”Filing with regulators · SEC filing · Nov 9
Cash$531M, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into 2028”

Key facts on OCUL

Key facts on OCUL
Holding it backSales down 10% on the year
Latest filing8-K, Nov 9 Reported its quarterly results

OCUL in the news

Mon Nov 9OCUL: Ocular Therapeutix Inc. filed SEC Form 8-K: Leadership Update quantisnow.com and 1 more · yesterday 7:21 AM ET OCUL closed +3.9% that day.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$531M, about 8 quarters (2 years) at the last year's spendingOn Sep 30 · the company says “into 2028”

OCUL catalysts

Coming up

After its last 4 reports it closed +2.6% on average, higher 3 of 4 times.

4 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for OCUL, and how long its cash lasts

Next step the company has named

Q4 2026“NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis”Filing with regulators · SEC filing · Nov 9

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPhase 3 · Active · 825 people · main data estimated Jan 8, 2027 · NCT06495918

3 more trials, 1 more milestone and 32 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 8 quarters

$531M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2028” (8-K, Nov 9).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Sep 30, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Business Officer Namrata Saroj sold 35,370 shares on Nov 5, under a planned sale. 24 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Pravin Dugel’s 15 filings and quotes.

Get an alert when OCUL files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How OCUL ranks in Biotech

OCUL is #241 of 273 by Quality Score.

How OCUL ranks in Biotech
RankStockQuality Score
241Ocular Therapeutix (OCUL) logoOCULOcular Therapeutix-8

Net income over four quarters: OCUL -$327M, LXRX -$62.4M, VIR -$185M, OLMA -$236M.

More in Biotech

When does OCUL report earnings, and what happens after?

Expected to report Thu Feb 4, before the open (in 75 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What OCUL reported on Nov 9, 2026

The quarter

Sales of $12.9M, 11% less than a year ago; a loss of $0.42 a share, from $0.38.

“Selling and marketing expenses were $15.7 million for the third quarter of 2026, compared with $13.1 million for the comparable quarter of 2025, reflecting an increase in personnel and pre-commercial investments to prepare for a potential AXPAXLI wet AMD launch.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

OCUL's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “General and administrative expenses were $18.8 million for the third quarter of 2026, compared with $16.0 million for the comparable quarter of 2025 reflecting increased personnel costs and additional infrastructure to support an increased scope of clinical trials and manufacturing expansion.”

From its results filing (SEC filing · Nov 9)

The numbers

Market value
$1.3B
today
Sales
$50.4M
down 9.7% on the year
Free cash flow
-$267M
last 12 months

Sales grew 0.3% a year over 3 years, fiscal 2022 to 2025.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on OCUL: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.6%+2.8%+3.9%
May 5Aug 3Nov 9
ReportedGapReaction5
days
Nov 9, 2026Before open-5.2%+3.9%-5.8%
Aug 3, 2026Before open+1.4%+2.8%+12.5%
May 5, 2026Before open-4.4%-0.6%-5.0%

OCUL closed higher after 3 of its last 4 reports.

All 4 reports, and OCUL's Quality Score going into each

OCUL sales and profit by year

Sales and profit by year

Sales grew in six of the last seven years, to $52M in 2025. It lost money in each of the eight years.

Nothing is firing on OCUL right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on OCUL, and all 14 on every stock.Get in free →See the top 3 →Start Pro

OCUL RSI on Nov 20: 30.6, below its 50-day and 200-day averages

Not scored

RSI 30.6, MACD below signal, below both averages. Not scored.

The deep dive on OCUL

  • What it does and how it makes money6 findingsAn operating loss of $270M in fiscal 2025, on $52.0M of sales.Annual report, filed Feb 5, 2026"We are also entitled to receive tiered, escalating royalties on the net sales of the AffaMed Licensed Products ranging from a low-teen to low-twenties percentage." (10-K for fiscal 2025)SEC filing · Feb 5, 2026"We own an issued patent in the United States that covers this product candidate, with a current expiration date in 2044 as well as corresponding pending U.S. and foreign counterpart applications …" (10-K for fiscal 2025)SEC filing · Feb 5, 2026
  • Where it stands2 findingsFor Pro members2 findings on where OCUL stands: its cash, debt, and share count, for Pro members
  • What changed in its filings9 findings"On March 20, 2026, plaintiff EyePoint, Inc., which we refer to as EyePoint, filed a lawsuit against us in Middlesex County Superior Court of Massachusetts." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 9, 2026A new heading in its "Risk Factors" this year: "Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 5, 2026, against the one of Mar 3, 2025One customer made up 42% of its revenue in fiscal 2025, down from 44% in fiscal 2024.SEC filing · Feb 5, 2026
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades OCUL, for Pro members
  • Against its closest peers4 peersNet income over four quarters: OCUL -$327M, LXRX -$62.4M, VIR -$185M, OLMA -$236M.

13 more findings on OCUL, each with its source, for Pro members.

OCUL share count over time

23% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of OCUL outstanding, as filed
Shares
outstanding
As
of
220MNov 6, 2026
219.6MJul 31, 2026
219MMay 1, 2026
217.7MFeb 2, 2026
Offerings, shelves, and splits of OCUL, from its filings
From its
filings
Filed
Priced a sale of sharesSep 30, 2025
Registered shares for a later sale (S-3ASR)Sep 30, 2025
Registered shares for a later sale (S-3ASR)Mar 25, 2024
Raised $100.1M in a sale of shares, about 8% of its market valueDec 14, 2023

OCUL insider trades

One insider sold $11K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellDonald Notman$11KChief Operating Officerat $10.24 on Aug 31, filed Sep 2

OCUL's officers and directors

Officers and directors with a Form 4 in the last 12 months.

10 more officers and directors file at OCUL.

See insider trades by person

Which ETFs hold OCUL?

In ETFs: OCUL is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

325 employeesBedford, MAocutx.com

What Ocular Therapeutix says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”

From its annual report, SEC filing · Feb 5, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on OCUL and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn OCUL's score around: 9 things
  • 8 more filings explained, a plain line each
  • 5 more things pulling OCUL's score down
BreakawaySep 2Donald Notman sold OCUL$11K at $10.24, filed Sep 2

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: OCUL's Quality Score is -8 (Poor), #241 of 273 in Biotech. Insiders sold $11K in the last 6 months (Form 4).

What does OCUL's Quality Score say?

OCUL scores -8 today, which Breakaway calls Poor. It is #241 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 48% in 3 months while the S&P 500 fell 10%. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is OCUL's Quality Score?

OCUL scores -8 today, which Breakaway calls Poor (below zero). That is #241 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OCUL's -8.

Are insiders buying OCUL?

One insider sold $11K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Donald Notman, Chief Operating Officer, who sold $11K on Aug 31.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Ocular Therapeutix: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.